felodipine has been researched along with Cerebrovascular Disorders in 8 studies
Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.
felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.
Cerebrovascular Disorders: A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.
| Excerpt | Relevance | Reference |
|---|---|---|
| "All clinical studies of at least 1 week's duration with felodipine in patients with hypertension were included in a safety analysis." | 7.69 | Overview of the safety of felodipine based on clinical trials in patients with hypertension. ( Elmfeldt, D; Elvelin, L; Niklasson, A; Olsson, G; Welin, L, 1997) |
| " All patients were randomly assigned to take aspirin 75 mg/day or placebo, and patients in the aspirin group had a 15% lower rate of major cardiovascular events and myocardial infarctions than did patients who received placebo." | 6.19 | Aggressive blood pressure lowering is safe, but benefit is still hard to prove. ( Pohl, MA; Vidt, DG, 1999) |
| " the level of blood pressure associated with the lowest incidence of major cardiovascular events such as fatal and non-fatal stroke and myocardial infarction and other cardiovascular mortality); and (2) to assess the effect of a low dose of acetylsalicylic acid (aspirin) compared with placebo on major cardiovascular events." | 5.09 | The Hypertension Optimal Treatment study and the importance of lowering blood pressure. ( Hansson, L, 1999) |
| "In 102 patients with high risk (52 patients with history of myocardial infarction, 50 patients with history of cerebral stroke within previous 6-48 months) arterial hypertension (AH) we studied clinical efficacy on angiotensin converting enzyme inhibitor (ACEI) lisinopril, calcium antagonist felodipine, and nonselective - -blocker carvedilol in dependence on salt sensitivity of AH." | 3.76 | [Comparative eficacy of antihypertensive therapy in patients with arterial hypertension and various sensitivity to salt]. ( Babkin, AP; Gladkikh, VV; Gulaia, GI; Pershukov, IV, 2010) |
| " To study further the interactions between dietary salt intake and antihypertensive drug treatment, we examined the effects of felodipine, a dihydropyridine derivative Ca2+ channel antagonist with natriuretic properties, on blood pressure and the development of left ventricular hypertrophy in the stroke-prone spontaneously hypertensive rats during different levels of sodium chloride in the diet." | 3.69 | Cardiovascular effects of felodipine are not antagonized by dietary salt. ( Karppanen, H; Laakso, J; Mervaala, EM, 1994) |
| "All clinical studies of at least 1 week's duration with felodipine in patients with hypertension were included in a safety analysis." | 3.69 | Overview of the safety of felodipine based on clinical trials in patients with hypertension. ( Elmfeldt, D; Elvelin, L; Niklasson, A; Olsson, G; Welin, L, 1997) |
| "Because hypertension is a risk factor for stroke, and because severe BP elevation may increase oedema and the risk of haemorrhage, acute antihypertensive therapy might seem reasonable." | 1.29 | [Reducing hypertension may worsen symptoms of acute apoplexy]. ( Garde, E; Jørgensen, HS; Lassen, NA; Olsen, TS, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (87.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Babkin, AP | 1 |
| Gladkikh, VV | 1 |
| Pershukov, IV | 1 |
| Gulaia, GI | 1 |
| Garde, E | 1 |
| Jørgensen, HS | 1 |
| Olsen, TS | 1 |
| Lassen, NA | 1 |
| Mervaala, EM | 1 |
| Laakso, J | 1 |
| Karppanen, H | 1 |
| Welin, L | 1 |
| Elvelin, L | 1 |
| Niklasson, A | 1 |
| Olsson, G | 1 |
| Elmfeldt, D | 1 |
| Gueyffier, F | 1 |
| Boissel, JP | 1 |
| Parving, HH | 1 |
| Vidt, DG | 1 |
| Pohl, MA | 1 |
| Hansson, L | 1 |
1 review available for felodipine and Cerebrovascular Disorders
| Article | Year |
|---|---|
Aggressive blood pressure lowering is safe, but benefit is still hard to prove.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1999 |
2 trials available for felodipine and Cerebrovascular Disorders
| Article | Year |
|---|---|
Aggressive blood pressure lowering is safe, but benefit is still hard to prove.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1999 |
The Hypertension Optimal Treatment study and the importance of lowering blood pressure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1999 |
6 other studies available for felodipine and Cerebrovascular Disorders
| Article | Year |
|---|---|
[Comparative eficacy of antihypertensive therapy in patients with arterial hypertension and various sensitivity to salt].
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Carbazoles; Carvedil | 2010 |
[Reducing hypertension may worsen symptoms of acute apoplexy].
Topics: Acute Disease; Aged; Cerebrovascular Disorders; Diltiazem; Felodipine; Humans; Hypertension; Male; R | 1995 |
Cardiovascular effects of felodipine are not antagonized by dietary salt.
Topics: Animals; Blood Pressure; Cerebrovascular Disorders; Electrolytes; Felodipine; Heart Rate; Hemodynami | 1994 |
Overview of the safety of felodipine based on clinical trials in patients with hypertension.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Cerebrovascular Disorders; Double-Blind Method; F | 1997 |
Hypertension Optimal Treatment (HOT) trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel B | 1998 |
Hypertension Optimal Treatment (HOT) trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Blood Pressure; Calcium | 1998 |